New study aims to personalize breast cancer treatment using genetic risk scores
NCT ID NCT06650748
First seen Mar 31, 2026 · Last updated May 20, 2026 · Updated 12 times
Summary
This study looks at 100 women with early-stage HR+/HER2- breast cancer to see if adding CDK4/6 inhibitors to standard hormone therapy before surgery improves outcomes. Researchers use a genetic risk score and early changes in a cell growth marker (Ki-67) to decide who gets the extra drug. The goal is to find better ways to tailor treatment and reduce cancer recurrence risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.